RE:RE:RE:Oncological Joint Ventures hit record heights in 2021 For those that doubt we're not worth easily 2B$US just for the NMIBC indication, just think again.
We have a 3-4x larger pool of patients because TLD-1433 don't discriminate among patients like immunotherapies do.
GSK paid 650MM$US upfront payment + an additional 1.45B$US for a technology that could widen its pool of patients above 30%. All this, from a sample set of Ph. 1 data based on this:
EOS-448 showed preliminary signs of clinical activity as a monotherapy, including a partial response in one pembrolizumab-resistant melanoma patient, and stable disease in multiple patients
Dr Hal Barron, Chief Scientific Officer and President R&D, GSK, said: “Immuno-oncology has transformed cancer care but unfortunately less than 30% of patients respond to treatment with the current leading immune checkpoint inhibitors.